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Research
AbstrACt
Objective To determine ethnic differences in the 
progression of chronic kidney disease (CKD) and risk of 
end-stage renal failure (ESRF) and death in adults with 
type 2 diabetes mellitus (T2DM), and to identify predictors 
of rapid renal decline.
Design Observational community-based cohort study 
undertaken from 2006 to 2016 with nested case–control 
study.
setting 135 inner London primary care practices 
contributing to the east London Database.
Participants General practice-registered adults aged 
25–85 years with established T2DM and CKD at baseline.
Outcomes The annual rate of renal decline was compared 
between white, south Asian and black groups, and 
stratified by proteinuria and raised blood pressure (BP) at 
baseline. Predictors of rapid renal decline were identified 
in a nested case–control study. Cox proportional hazards 
regression was used to determine ethnic differences in the 
risk of ESRF and death.
results Age–sex adjusted annual decline was greatest 
in the Bangladeshi population. There was stepwise 
increase in the rate of decline when stratifying the 
cohort by baseline proteinuria and BP control, with south 
Asian groups being most sensitive to the combined 
effect of proteinuria and raised BP after accounting for 
key confounders. The odds of rapid renal decline were 
increased for individuals of Bangladeshi, African and 
Caribbean ethnicity, those with hypertension, proteinuria, 
cardiovascular disease and with increasing duration of 
diabetes. Rapid progression was more frequent in younger 
age groups. Risk of developing ESRF was highest in the 
black group compared with the white group (HR 1.88, 
95% CI 1.11 to 3.19). Risk of death from any cause was 
29% lower in the south Asian group compared with the 
white group (HR 0.71, 95% CI 0.56 to 0.91).
Conclusions Proteinuria and hypertension trigger 
accelerated estimated glomerular filtration rate decline 
differentially by ethnicity. Active monitoring of younger 
adults, who have greater odds of rapid progression and the 
most to gain from interventions, is essential.
IntrODuCtIOn  
Chronic kidney disease (CKD) is a common 
complication of diabetes mellitus. In the 
UK, it is estimated that up to 30% of patients 
with type 2 diabetes mellitus (T2DM) have 
CKD stages 3–5.1 Ethnic minority groups 
are known to have a higher prevalence of 
T2DM and end-stage renal failure (ESRF) 
compared with the white majority popu-
lation.2 3 Whether this excess of ESRF is a 
result of faster progression of CKD in ethnic 
minority groups remains poorly understood.4 
In the USA, higher rates of decline among 
black groups have been observed which may 
be related to social deprivation or differences 
in access to healthcare.5 6 In the UK and the 
Netherlands, where access to healthcare is 
universal, studies have reported both faster 
decline in non-white groups7–10 and equiva-
lent decline between ethnic groups.11 12
strengths and limitations of this study
 ► Completeness of ethnicity recording was over 90% 
in the study population, allowing a rare opportunity 
to conduct an in-depth exploration of differences 
between both high-level ethnic groups and constit-
uent subgroups.
 ► Study patients comprised 98% of the eligible gen-
eral  practice-registered population, came from a 
single contiguous geographical area, and thus were 
representative of the wider east London population.
 ► The median follow-up of 9 years was higher than 
for database studies of general populations, as in-
dividuals with established type 2 diabetes mellitus 
tend to be older and less geographically mobile than 
younger population groups.
 ► As with any observational database study using rou-
tinely collected clinical data, some individuals had 
missing or erroneous data for the variables of inter-
est, with patterns of missing-ness likely related to 
duration and severity of disease.
 ► Our inability to capture predictors not available in 
routine primary care data such as over-the-counter 
medications, hospital admissions, patient frailty and 
biomarkers may have resulted in unmeasured resid-
ual confounding.
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Hypertension and proteinuria are known to accel-
erate the progression of renal decline13–15; whether these 
factors and other predictors such as cardiovascular disease, 
smoking status, body mass index (BMI) and medication 
use act differentially between ethnic groups has yet to be 
explored. The identification of modifiable risk factors for 
deterioration in renal function is important for optimal 
review and management in primary care and the effective 
use of specialist services. This is of particular importance 
as the UK population ages and becomes more ethnically 
diverse.
The aim of this study was to establish the role of ethnicity 
alongside other major risk factors in the progression 
of CKD in people with T2DM managed in community 
settings. Secondary aims included identifying predictors 
of rapid renal decline (>5 mL/min/1.73 m2 of estimated 
glomerular filtration rate (eGFR) a year) and ethnic 
differences in the risk of developing ESRF and death.
MAterIAls AnD MethODs
setting and population
The study was set in the three geographically contiguous 
East London clinical commissioning groups (CCGs) of 
Newham, Tower Hamlets and City and Hackney. Patients 
were registered with 134 general practices (GPs), with a 
combined GP-registered population of 912 668 patients 
in 2011 (the midpoint of this study). This practice data 
covered more than 98% of the GP-registered population 
in the three CCGs. According to the 2011 UK census, 
58% of the population in the study area were identified 
as being of non-white ethnic origin.16 Practice computer 
databases were interrogated using EMIS Web software.17 
Demographic and clinical data were obtained for the 
period 2006–2016 for all adult patients with a diagnostic 
Read code for T2DM. Patients were included in the study if 
they had an eGFR of between 15 and 60 mL/min/1.73 m2 
on two or more readings at least 3 months apart following 
their initial T2DM diagnosis, could provide three or 
more years of follow-up data and were between 25 and 85 
years of age at entry to the study. Patients with diagnostic 
Read codes for haemodialysis or peritoneal dialysis, 
or ESRF prior to entry to the study were excluded (see 
online supplementary figure 1 for population inclusion 
flow chart). All data were anonymised and managed 
according to UK National Health Service information 
governance requirements.
study design
This was an observational cohort study using prospec-
tively collected electronic primary care data from the 
East London Database.18 CKD onset (stage 3 or below) 
was defined as the date of the latest of the first two eGFR 
readings between 15 and 60 mL/min/1.73 m2 recorded 
at least 3 months apart. All eGFR values were calculated 
from recorded creatinine values in the patient record 
using the four variable modification of diet in renal 
disease (MDRD) equation, which adjusts for gender and 
black ethnicity, and is used widely in UK primary and 
secondary care.19 Values recorded between 2003 and 
2005 were used to identify CKD onset prior to the start 
of the study period while values recorded from 2006 to 
2016 were used to identify CKD onset during the study 
period. For patients with CKD onset before the start of the 
study period, follow-up commenced on 1 April 2006. For 
patients who developed CKD after 1 April 2006, follow-up 
commenced on the date of CKD onset. For the analysis of 
eGFR decline over time and risk of ESRF, the follow-up 
period ended at the earliest of: dialysis commencement, 
diagnosis of ESRF, death, deregistering from the prac-
tice or 1 April 2016. For the analysis of risk of death, the 
follow-up period ended at the earliest of death, de-regis-
tering from the practice or 1 April 2016.
exposures
T2DM diagnoses were identified via the C10F% Read 
code on the electronic health record. Self-reported 
ethnicity recorded at the practice during registration or 
routine consultation was identified via the 9i% and 9 S% 
Read codes. Read codes for ethnicity were collapsed into 
the 16 categories of the UK 2001 census. For this study, 
ethnicity was considered in two ways; first in the three 
high-level categories of white, south Asian and black, and 
second, with the non-white groups further broken down 
into Indian, Pakistani, Bangladeshi, African and Carib-
bean. Individuals of mixed ethnicity were grouped with 
their parent ethnic minority. For example, individuals 
who had classified themselves as mixed white and African 
were classed as African for the purposes of this study. 
Patients with other, unknown or missing ethnicity were 
not included in the analysis. The Townsend score (derived 
from census variables and linked to patient place of resi-
dence) was used as a measure of social deprivation.20
Outcomes
For the analysis of ethnic differences in progression 
towards ESRF, the outcome of annual change in eGFR 
was determined by calculating a single eGFR value for 
each year of follow-up, based on the average of all indi-
vidual eGFR values recorded in that year for each patient. 
If eGFR was missing in any 1 year, the average eGFR value 
from the previous year was brought forward.
For the nested case–control study identifying predictors 
of rapid renal decline, cases and controls were defined 
according to their overall eGFR progression which was 
calculated using the equation (baseline eGFR−final 
eGFR)/total years of follow-up), with baseline and final 
eGFR referring to the annualised average eGFR in the 
first and last years of follow-up.
Individuals in or above the 95th percentile for 
overall eGFR progression were considered rapid 
progressors. Within our study cohort, this equated to 
an average annual eGFR loss of ≥5 mL/min/1.73 m2 
(online supplementary table 1). ESRF was identified 
using Read codes for dialysis and ESRF, with date of 
onset defined as the earliest entry of either code on 
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the patient record. Death was identified using the date 
of patient d-registration, where the patients’ registra-
tion status was coded as ‘deceased’.
Covariates
Covariate data were extracted on 1st April of each study 
year between 2006 and 2016, and defined as the latest 
recorded value in the preceding 12 months. Covariates 
considered for analysis included age, gender, Index 
of Multiple Deprivation score, systolic blood pressure 
(SBP), glycated haemoglobin (HbA1c), proteinuria, 
smoking status, BMI, diagnosed cardiovascular disease 
(ischaemic heart disease, heart failure, stroke, peripheral 
vascular disease) and any prescription of ACE inhibitors 
and angiotensin receptor blockers (ARBs). Proteinuria 
was considered ‘positive’ if the patient had a protein:cre-
atinine ratio ≥15 mg/mmol, an albumin:creatinine ratio 
value ≥2.5 mg/mmol for men, or ≥3.5 mg/mmol for 
women, or a urine dipstick result ≥ ‘1+’. Raised blood 
pressure was considered to be an SBP reading of >130 mm 
Hg. Smoking status was dichotomised into current smoker 
and current non-smoker (see online supplementary table 
2 for code lists).
statistical analysis
All statistical analyses were performed using Stata V.14. 
For the analysis of ethnic differences in the annual rate 
of eGFR progression towards ESRF, annual change in 
eGFR was determined using a multilevel linear regression 
panel with continuous eGFR as the outcome and years 
of follow-up as the main predictor, with multiple obser-
vations nested within patients who were further nested 
within practices. The annual change in eGFR was calcu-
lated for the cohort as a whole and separately for each 
ethnic group in turn. All analyses were stratified by the 
presence of proteinuria and/or raised SBP at baseline 
and adjusted for both a priori variables as measured at 
baseline (age, sex, eGFR, ACE/ARB) and baseline vari-
ables found to be significantly associated with eGFR in 
univariable analysis (HbA1c, cardiovascular disease 
(CVD) and duration of diabetes).
Predictors of rapid renal decline towards ESRF were 
determined using a nested case–control study. Cases were 
defined as individuals who had an annual average eGFR 
decline of ≥5 mL/min/1.73 m2 per year based on the 
difference between their baseline and final eGFR values. 
Controls were defined as all individuals whose average 
annual rate of decline was below 5 mL/min/1.73 m2 per 
year. Logistic regression was used to determine the odds 
of having experienced rapid eGFR decline. The model 
was adjusted for a priori variables as measured at base-
line (age, gender, ethnic group, raised SBP, proteinuria, 
duration of diabetes, eGFR and ACE/ARB prescription) 
and baseline CVD, the only additional variable found to 
be significantly associated with rapid progression in the 
univariable analysis.
Cox proportional hazards regression modelling was 
used to determine ethnic differences in the risk of ESRF 
and risk of death. Both models were adjusted for a priori 
variables (age at baseline, gender, eGFR, ACE/ARB 
prescription, smoking status, SBP value, proteinuria and 
duration of diabetes at baseline) and variables found to 
be significantly associated with ESRF and death in the 
univariable analysis (BMI, HbA1c, CVD, deprivation). 
The analysis for risk of death was additionally adjusted for 
dialysis/ESRF. Age, diabetes duration, ethnicity, gender 
and deprivation were treated as time-constant variables. 
All other variables were time-updated in each year of 
follow-up to account for temporal changes in values, inci-
dent diagnoses or initiation of treatment during follow-up. 
For the risk of ESRF, a competing risks framework was 
employed as death may have competed with ESRF, the 
outcome of interest. For the risk of death, a standard Cox 
regression model was used as ESRF does not preclude the 
outcome of interest occurring.
results
From 120 591 adults with T2DM identified in the East 
London practice database between 2006 and 2016, 6274 
individuals of white, south Asian or black African/Caribbean 
ethnicity with CKD, aged 25–84 years and free from ESRF/
dialysis at baseline were eligible for inclusion in the study 
(online supplementary figure 1). Mean follow-up time was 
9.0 years. Both south Asian and black groups had a longer 
duration of diabetes and a higher HbA1c value at baseline 
compared with the white group. Baseline eGFR was similar 
between ethnic groups; prevalence of proteinuria and hyper-
tension at baseline was highest in the black African/Carib-
bean group and lowest in the south Asian group (table 1).
ethnic differences in eGFr decline
The annual age–sex-adjusted rate of eGFR decline for 
the whole cohort was −0.86 mL/min/1.73 m2 (95% CI 
−0.89 to –0.83). When broken down by ethnic group, 
decline was significantly faster in the south Asian group 
relative to the white group and significantly slower in 
the black group. When broken down further by ethnic 
subgroup, annual change in eGFR was significantly 
faster in the Bangladeshi group compared with the 
Indian group, and comparable between African and 
Caribbean groups (figure 1).
stratification by risk factor control
Stratification by baseline blood pressure and proteinuria 
status showed that the rate of eGFR decline was faster in 
those with proteinuria alone compared with hypertension 
alone, and fastest overall for individuals with both. South 
Asian patients were found to be most sensitive to the 
combined effect of proteinuria and hypertension after 
accounting for key confounders (−1.94 mL/min/1.73 m2, 
95% CI −2.15 to –1.73) (table 2). Further stratification by 
ethnic subgroup revealed significant heterogeneity in the 
effects of hypertension and proteinuria on eGFR decline, 
with no clear patterns evident (online supplementary 
material table 2).
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Predictors of rapid eGFr decline
After stratifying the study population by overall eGFR 
decline, 3.4% of white patients, 4.9% of South Asian 
patients and 6.8% of black patients were identified 
as rapid progressors (crude annual decline in eGFR 
of ≥5 mL/min/1.73 m2) (table 3 and figure 2). After 
adjustment for known confounders, the odds of having 
rapid progression were found significantly raised in 
African, Caribbean and Bangladeshi groups relative 
to the white group, with the OR largest for the African 
group (OR 2.53, 95% CI 1.63 to 3.92). The odds of rapid 
decline were doubled for patients aged 25–54 years (OR 
1.96, CI95% 1.34 to 2.85) and raised by 38% for those 
aged 55–64 years (OR 1.38, CI95% 0.99 to 1.92) relative 
to those aged 65–74 years. Both raised blood pressure 
and proteinuria were independently associated with 
increased odds of being a rapid progressor, as was the 
presence of CVD at baseline. The odds of rapid progres-
sion increased with each category of diabetes duration, 
relative to those with the shortest duration (table 4).
ethnic differences in the risk of esrF
The risk of ESRF was more than doubled in the black 
groups relative to the white group in a fully adjusted anal-
ysis which also took account of the competing risk of death 
(HR 2.23, 95% CI 1.25 to 2.98). When broken down further 
by ethnic subgroup, the increased risk was apparent in both 
the African and Caribbean groups relative to the white 
group (African HR 2.29, 95% CI 1.12 to 4.64; Caribbean 
HR 2.20, 95% CI 1.14 to 4.27) (table 5).
Table 1 Baseline characteristics and outcome measures for the study population
Baseline characteristics
N with 
complete 
data White South Asian Black
P values, 
SA vs white
P values, 
black vs 
white
  N 6274 2447 2732 1095
  Mean years of follow-up (SD) 6274 9.2 (2.2) 8.8 (2.3) 9.0 (2.3) <0.001 <0.001
Diabetes characteristics
  Diabetes duration at baseline, 
mean (SD)
6274 7.8 (6.7) 9.9 (7.7) 10.8 (8.3) <0.001 <0.001
Baseline measures
  Men, % 6274 41.9 48.4 42.5 <0.001 0.73
  Mean age (SD) 6274 69.5 (9.3) 65.5 (9.9) 67.8 (10.0) <0.001 <0.001
  Mean systolic blood pressure (SD) 6022 135.3 (17.1) 133.2 (17.8) 138.8 (18.2) <0.001 <0.001
  Mean diastolic blood pressure (SD) 6022 74.3 (10.0) 73.9 (10.0) 76.5 (10.2) 0.312 <0.001
  Mean HbA1c (IFCC aligned) (SD) 5346 58.8 (16.4) 63.1 (17.4) 63.0 (20.7) <0.001 <0.001
  Current smokers, % 5882 16.2 12.9 7.0 0.001 <0.001
  Positive proteinuria, % 4627 33.2 30.0 36.6 <0.001 0.515
CKD stage at baseline (based on eGFR)
  Mean eGFR, mL/min/1.73 m2 (SD) 6274 51.2 (8.2) 51.6 (8.3) 51.8 (8.1) 0.088 0.051
  Stage 3a 81.5 82.9 83.6 0.16 0.129
  Stage 3b 15.7 13.9 13.2
  Stage 4 2.8 3.2 3.2
Baseline medication use (ever prescribed in the 12 months preceding)
  ACE/ARB 6274 81.7 82.2 85.3 0.686 0.009
Baseline comorbidities
  Coded hypertension or SBP 
>130 mm Hg, %
6274 88.4 75.0 94.8 <0.001 <0.001
  CVD (CHD, stroke, heart failure, 
PVD), %
6274 42.8 40.0 30.2 0.045 <0.001
Outcome measures
  Rapid decline (>5 mm/mol), % 6274 3.4 4.9 6.8 0.006 <0.001
  ESRF/dialysis, % 6274 2.3 4.3 4.7 <0.001 <0.001
  Death, % 6274 18.8 12.2 12.7 <0.001 <0.001
Baseline date is defined as the latest date of CKD onset or 1 April 2006.
ARB, angiotensin receptor blocker; CHD, coronary heart disease; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, 
estimated glomerular filtration rate; ESRF, end-stage renal failure; HbA1c, glycated haemoglobin; IFCC, International Federation of Clinical 
Chemistry; PVD, peripheral vascular disease; SA, South Asian; SBP, systolic blood pressure.
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ethnic differences in the risk of death
After accounting for age, sex, deprivation, HbA1c, BMI, 
smoking status, eGFR, proteinuria, CVD, ACE/ARB 
prescriptions, ESRF and diabetes duration, risk of death 
was significantly reduced in the South Asian population 
relative to the white group (HR 0.71, 95% CI 0.56 to 
0.91), with decreased risk driven entirely by the Bangla-
deshi population (HR 0.63, 95% CI 0.46 to 0.86). No 
differences in the risk of death between white and black 
groups was found (table 6).
DIsCussIOn
This observational study of over 6000 primary care 
patients followed for an average of 9 years represents the 
largest UK-based study examining ethnic differences in 
Figure 1 Age–sex-adjusted eGFR progression rate by ethnic group. eGFR, estimated glomerular filtration rate .
Table 2 Fully adjusted eGFR progression rate stratified by baseline blood pressure and proteinuria status for the main ethnic 
groups
Baseline SBP ≤130 Baseline SBP >130
Ethnic 
group N
eGFR change 
per year mL/
min/1.73 m2 95% CI P values N
eGFR change 
per year mL/
min/1.73 m2 95% CI P values
Whole 
population
Proteinuria 
negative
−0.64 (−0.96 to –0.59) <0.001 −0.92 (−1.97 to –0.87) <0.001
White 888 −0.57 (−0.65 to –0.49) <0.001 1209 −0.96 (−1.04 to –0.89) <0.001
South Asian 1126 −0.74 (−0.82 to –0.679) <0.001 1040 −0.96 (−1.03 to –0.89) <0.001
Black 365 −0.51 (−0.64 to –0.38) <0.001 552 −0.78 (−0.89 to –0.67) <0.001
Whole 
population
Proteinuria 
positive
−1.38 (−1.56 to –1.21)
<0.001
−1.59 (−1.73 to –1.44)
<0.001
White 145 −0.91 (−1.25 to –0.57) <0.001 204 −1.33 (−1.57 to –1.08) <0.001
South Asian 256 −1.53 (−1.76 to –1.30) <0.001 307 −1.94 (−2.15 to –1.73) <0.001
Black 61 −1.55 (−2.01 to –1.10) <0.001 115 −1.15 (−1.53 to –0.77) <0.001
Model adjusted for age, sex and baseline measures of HbA1c, eGFR, CVD, ACE/ARB and diabetes duration.
ARB, angiotensin receptor blocker; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HbA1c, glycated 
haemoglobin; SBP, systolic blood pressure.
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progression of CKD in a community-managed diabetic 
cohort. We identified an overall annual decline of 
−0.86 mL/min. We showed that while South Asian 
patients, particularly of Bangladeshi ethnicity, had the 
greatest annual loss of eGFR and significantly reduced 
risk of death relative to white groups, black groups were 
most at risk of rapid CKD progression and had the highest 
risk of developing ESRF.
This study is consistent with other studies showing 
significantly faster renal progression and lower risk of 
death in South Asian groups compared with white groups. 
A Canadian study of 3444 patients referred to nephrology 
clinics with CKD found that South Asian groups had a 
higher risk of progressing to ESRF than white groups 
(HR 1.35, p<0.05) and a lower risk of all-cause mortality 
(HR 0.69, p<0.05). However, in contrast to our cohort, 
this study was not restricted to patients with established 
T2DM, was not a community-managed cohort and did 
not include individuals of black ethnicity.21
The average annual rate of renal decline was found 
to be equivalent between white, African and Caribbean 
populations in our study, even after adjustment for key 
confounders and stratification by proteinuria and raised 
blood pressure status. Equivalence in renal decline and 
risk of death between black and white populations has 
been reported recently in the USA.22 23 Ethnic differences 
in CKD progression and outcomes may be attenuated in 
settings where patients of different ethnic groups have 
equal access to care and equitable management of risk 
factors such as blood pressure, CVD risk and proteinuria. 
In countries such as the UK, Canada and the Netherlands, 
access to primary healthcare is free at the point of need, 
a key factor in reducing inequalities in health outcomes. 
A recent meta-regression of 1.1 million adults from 45 
cohorts found that the risk of all-cause mortality, ESRF 
and low eGFR was comparable between Asian, white and 
black ethnic groups though this study included a number 
of large non-diabetic cohorts which may account for the 
lack of difference between white and Asian populations.24
Though average annual decline was found to be 
comparable between white and black Caribbean ethnic 
groups, the odds of having rapid eGFR progression was 
found significantly raised for black groups relative to 
white. This apparent inconsistency may be explained by 
the fact that a single measure of average annual decline 
in each ethnic group may mask heterogeneity in eGFR 
trajectory. Over the study follow-up period, patients 
either lost eGFR, remained at a stable eGFR or gained 
eGFR. In our study population, the proportion of patients 
belonging to each of these categories varied by ethnic 
group. Black patient were over-represented in both the 
increasing eGFR category and the rapid decline category 
relative to the white and South Asian groups (figure 2).
Bangladeshi ethnicity, hypertension, proteinuria, 
diabetes duration and CVD were also independently 
associated with the increased odds of having rapid renal 
decline, after mutual adjustment for all risk factors 
captured in the study. For diabetes duration, a dose–
response relationship was apparent. Significantly, we 
noted an inverse relationship between age and rapid 
Table 3 Annual change in estimated glomerular filtration rate (eGFR) by ethnic group based on overall progression (%)
eGFR change White South Asian Indian Pakistani Bangladeshi Black African Caribbean Total
Controls
Increase/stable 41.7 39.4 37.5 35 41.6 42.6 45.8 41.1 40.8
1–4 mL/min/1.73 m2 decrease 55.0 55.7 59 61.4 52 50.6 44.9 55.3 54.6
Cases 5–21 mL/min/1.73 m2 decrease 3.4 4.9 3.5 3.6 6.4 6.8 9.3 5.6 4.7
Figure 2 Crude annual change in estimated glomerular filtration rate based on overall progression (mL/min/1.73 m2).
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progression, highlighting the importance of regular scru-
tiny and active management for those individuals who 
develop CKD prior to the age of 65 years.
strengths
The recording of ethnicity was incentivised across 
the UK from 2006 to 2016, resulting in over 90% 
completeness of ethnicity recording for patients 
with T2DM in our electronic health database during 
the study period. This allowed us a rare opportunity 
to conduct an in-depth exploration of differences 
in both high-level ethnic groups and constituent 
subgroups. Patients contributing to the study were 
registered with primary care practices in a single 
contiguous geographical area which were unse-
lected, and hence representative of East London. As 
the East London database has been capturing patient 
Table 4 Multivariable analysis of risk factors for rapid progression (≥5 mL/min/year)
N Rapid Per cent aOR* 95% CI P values
Ethnic group
White (reference) 2446 82 3 1.00 –
South Asian 2729 133 5 1.28 (0.96 to 1.71) 0.098
  Indian 822 29 4 0.92 (0.60 to 1.44) 0.753
  Pakistani 414 15 4 0.95 (0.55, to 1.71) 0.905
  Bangladeshi 1242 80 6 1.70 (1.23 to 2.38) 0.001
Black 1093 74 7 1.93 (1.39 to 2.70) <0.001
  African 356 33 9 2.53 (1.64 to 3.93) <0.001
  Caribbean 737 41 6 1.63 (1.10 to 2.40) 0.016
Age at baseline
  25–54 723 50 7 1.96 (1.34 to 2.85) <0.001
  55–64 1405 67 5 1.38 (0.99 to 1.92) 0.057
  65–74 (reference) 2497 95 4 1.00 – 
  75–85 1643 77 5 1.30 (0.95 to 1.79) 0.103
Gender
  Female (reference) 3459 135 4 1.00 – 
  Male 2809 154 5 1.26 (0.98 to 1.61) 0.072
Baseline SBP
  <130 mm Hg 
(reference)
2841 108 4 1.00 – 
  ≥130 mm Hg 3427 181 5 1.52 (1.18 to 1.96) 0.001
Baseline proteinuria
  No (reference) 5180 204 4 1.00 – 
  Yes 1088 85 8 1.74 (1.32 to 2.30) <0.001
Duration of diabetes
  0–4 years (reference) 2299 67 3 1.00 – 
  5–9 years 1531 75 5 1.64 (1.17 to 2.32) 0.005
  10–19 years 1820 105 6 1.89 (1.36 to 2.61) <0.001
  20+ years 618 42 7 1.99 (1.30 to 3.04) 0.002
Baseline eGFR 1.00 (0.99 to 1.02) 0.829
ACE/ARB at baseline
  No (reference) 1176 50 4 1.00 – 
  Yes 5092 239 5 0.89 (0.64 to 1.25) 0.513
CVD at baseline
  No (reference) 3957 153 4 1.00 – 
  Yes 2311 136 6 1.45 (1.13 to 1.87) 0.004
*All variables are mutually adjusted for one another.
aOR, adjusted OR; ARB, angiotensin receptor blocker; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; SBP, systolic 
blood pressure. 
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data since 2006, our study included patients with up 
to 10 years of follow-up. The median follow-up of 9 
years is higher than for database studies of general 
populations, as individuals with established T2DM 
tend to be older, and less geographically mobile than 
younger population groups. The MDRD formula for 
calculating the eGFR was chosen for this study as it is 
the standard across primary and secondary cares in 
the UK, and thus findings using this measure are of 
relevance to clinicians working in these settings.
limitations
As with any observational database study using routinely 
collected clinical data, some individuals had missing 
data for the variables of interest, and there will be 
some coding errors. Missing data may be at random 
but non-random missing data is possible—related both 
to patient behaviour and disease severity.25–28 Smaller 
sample sizes in the ethnic subgroups means we may 
have been underpowered to detect meaningful differ-
ences in progression, rapid decline and death. Our 
inability to capture predictors not available in routine 
primary care data such as over-the-counter medications, 
hospital admissions, patient frailty and biomarkers may 
have resulted in unmeasured residual confounding. For 
example, regular use of non-steroidal anti-inflamma-
tory drugs is associated with CKD progression. However, 
due to widespread availability at pharmacies without 
a prescription, we are unable to accurately quantify 
exposure to this drug from electronic health records 
alone. Mortality was identified using patient registra-
tion information on the electronic record but was not 
confirmed using linked Office for National Statistics 
(ONS) mortality data which may have led to an under-
estimate of death events. Linkage between electronic 
health record databases and administrative data has 
been shown to improve the validity and completeness of 
coded information.29 30 Due to small sample sizes in the 
constituent ethnic subgroups once further stratified by 
raised blood pressure and proteinuria, it was difficult to 
discern any clear trends in the average annual decline.
Table 5 Relative risk of ESRF/dialysis by ethnic group (competing risks analysis)
Variable N ESRF Per cent Adjusted HR* 95% CI P values
Whole population 6274 224 4
White (reference) 2447 57 2 1 – – 
South Asian 2729 116 4 1.33 (0.79 to 2.25) 0.276
  Indian 822 30 4 1.24 (0.63 to 2.43) 0.529
  Pakistani 415 10 2 1.09 (0.48 to 2.49) 0.843
  Bangladeshi 1244 63 5 1.49 (0.83 to 2.66) 0.182
Black 1095 51 5 2.23 (1.25 to 3.98) 0.007
  African 357 19 5 2.29 (1.12 to 4.64) 0.022
  Caribbean 738 32 4 2.20 (1.14 to 4.27) 0.019
*Model adjusted for age, sex, Townsend deprivation score, HbA1c, BMI, smoking status, eGFR, proteinuria, CVD, ACE/ARB and diabetes 
duration. All measures except age and gender are time updating.
ARB, angiotensin receptor blocker; BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; ESRF, 
end-stage renal failure; HbA1c, glycated haemoglobin.
Table 6 Relative risk of death by ethnic group
Variable N Deaths Per cent Adjusted HR* 95% CI P values
Whole population 6274 930 15
White (reference) 2447 461 19 1.00 – – 
South Asian 2729 333 12 0.71 (0.56 to 0.91) 0.006
  Indian 822 104 13 0.81 (0.56 to 1.15) 0.239
  Pakistani 415 42 10 0.96 (0.59 to 1.55) 0.866
  Bangladeshi 1244 163 13 0.63 (0.46 to 0.86) 0.003
Black 1095 139 13 0.77 (0.57 to 1.05) 0.099
  African 357 29 8 0.79 (0.43 to 1.44) 0.445
  Caribbean 738 110 15 0.77 (0.55 to 1.08) 0.130
*Model adjusted for age, sex, Townsend deprivation score, HbA1c, BMI, smoking status, eGFR, proteinuria, CVD, ACE/ARB, dialysis/ESRF 
and diabetes duration. All measures except age and gender are time updating.
ARB, angiotensin receptor blocker; BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; ESRF, 
end-stage renal failure; HbA1c, glycated haemoglobin. 
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Implications for practice
This study has highlighted the importance of measuring 
proteinuria, and of monitoring and actively managing 
blood pressure to target among individuals with diabetic 
CKD. These key aspects of primary care management are 
well established in the UK31 and up to 2015 were finan-
cially incentivised in the Quality and Outcomes Frame-
work, a pay for performance programme across UK 
primary care.32 However, the recent national CKD audit in 
England and Wales has shown that only 54% of people with 
diabetes have an annual proteinuria measurement, and 
that 70% do not achieve blood pressure target measure-
ments.33 Some ethnic groups, particularly Bangladeshi, 
appear to be more sensitive to the combined effects of 
proteinuria and hypertension than other ethnic groups. 
Clinicians need to be aware that younger diabetics (<55 
years) with CKD are at twice the risk of rapid progression 
of CKD compared with those >65 years and thus need 
closer monitoring, management of risk factors and early 
specialist review to delay progression.
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